A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Durata Therapeutics International B.V.0 个研究点目标入组 698 人开始时间: 2014年7月9日最近更新: 2015年7月10日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 698

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male or female patients, 18-85 years of age.
•2. A personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
•3. Patients having an abSSSI (suspected or confirmed to be caused by Gram-positive bacteria) defined for purposes of this study as an infection either involving deeper soft tissue or requiring significant surgical intervention:
•(a) Major cutaneous abscess characterized as a collection of pus within the dermis or deeper that is accompanied by erythema, edema and/or induration which:
•i. requires surgical incision and drainage, and
•ii. is associated with cellulitis such that the total affected area involves at least 75 cm2 of erythema, and
•iii. is defined by a margin of erythema that is = 5 cm from the rim of induration or edema that defines the border of the abscess in all directions, or,
•iv. alternatively, involves the central face and is associated with an area of erythema of at least 50 cm2 and a margin = 3 cm in all directions from the abscess rim
•(b) Surgical site or traumatic wound infection characterized by purulent drainage with surrounding erythema, edema and/or induration which occurred within 30 days after the trauma or surgery and is associated with cellulitis such that
•i. the total affected area involves at least 75 cm2 of erythema, and
•ii. is defined by a margin of erythema in at least one direction that is = 5 cm from the edge of the wound, or
•iii. alternatively, involves the central face and is associated with an affected area of at least 50 cm2 and has a margin of erythema in at least one direction = 3 cm from the wound edge
•(c) Cellulitis, defined as a diffuse skin infection characterized by spreading areas of erythema, edema and/or induration and
•i. is associated with erythema that involves at least 75 cm2 of surface area, or
•ii. alternatively, cellulitis of the central face that is associated with an affected area of at least 50 cm2
•4. In addition to the requirement for erythema, all patients are required to have at least two (2) of the following signs of abSSSI
•(a) Purulent drainage/discharge
•(b) Fluctuance
•(c) Heat/localized warmth
•(d) Tenderness to palpation
•(e) Swelling/induration
•5. Patients must present with at least ONE of the following systemic signs of infection:
•(a) An elevated body temperature ? 38?C/100.4?F as measured by the patient/caregiver or investigator within 24 hours of baseline;
•(b) White blood cell count > 12,000 cells/mm3;
•(c) A manually performed white blood differential count with = 10% band forms, regardless of peripheral white blood cell count.
•6. Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 600
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 98

排除标准

•1. Patients with a contra-indication to the administration of dalbavancin (see Section 5.4.1) such as hypersensitivity to any of the glycopeptide agents.
•2. Females of child-bearing potential who are unable to take adequate contraceptive precautions, have a positive pregnancy result within 24 hours prior to study entry, are known to be pregnant, or are currently breastfeeding an infant.
•3. Patients with sustained shock defined as systolic blood pressure < 90 mm Hg for more than 2 hours despite adequate fluid resuscitation, with evidence of hypoperfusion or need for sympathomimetic agents to maintain blood pressure.
•4. Participation in another study of an investigational drug or device within 30 days prior to enrollment.
•5. Receipt of a systemically or topically administered antibiotic with a Gram-positive spectrum that achieves therapeutic concentrations in the serum or at the site of the abSSSI within 14 days prior to randomization. An exception is allowed for patients receiving a single dose of a short-acting (half-life = 12 hours) antibacterial drug prior to randomization; up to 25% of subjects may have received such therapy.
•6. Infection due to an organism known prior to study entry to be resistant to dalbavancin or vancomycin (vancomycin MIC > 8 ?g/mL).
•7. Patients with evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis; endovascular infection, such as clinical and/or echocardiographic evidence of endocarditis or septic thrombophlebitis.
•8. Infections caused exclusively by Gram-negative bacteria (without Gram-positive bacteria present) and infections caused by fungi, whether alone or in combination with a bacterial pathogen.
•9. Venous catheter entry site infection.
•10. Infections involving a diabetic foot ulceration, perirectal abscess or a decubitus ulcer.
•11. Patient with an infected device, even if the device is removed. Examples include infection of: prosthetic cardiac valve, vascular graft, a pacemaker battery pack, joint prosthesis, hemodialysis catheter, implantable pacemaker or defibrillator, intra-aortic balloon pump, left ventricular assist device, a peritoneal dialysis catheter, or a neurosurgical device such as a ventricular peritoneal shunt, intra-cranial pressure monitor, or epidural catheter.
•12. Gram-negative bacteremia, even in the presence of Gram-positive infection or Gram-positive bacteremia. Note: If a Gram-negative bacteremia develops during the study, or is subsequently found to have been present at Baseline, the patient should be removed from study treatment and receive appropriate antibiotic(s) to treat the Gram-negative bacteremia. Such patients must have an EOT visit performed within 3 calendar days after discontinuing study medication and are required to have AEs reported through Final Visit.
•13. Patients whose abSSSI is the result of having sustained full or partial thickness burns.14. Patients with an infection involving a limb with evidence of critical ischemia of an affected limb defined as any of the following criteria: absent or abnormal Doppler wave forms, toe blood pressure of < 45 mm Hg, ankle brachial index < 0.5, and/ or critical ischemia as assessed by a vascular surgeon.
•15. Patients with abSSSI such as superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or simple abscess that only requires surgical drainage for cure.
•16. Concomitant condition requiring any antibiotic therapy that would interfere with the

研究者

发起方

Durata Therapeutics International B.V.

相似试验

进行中（未招募）

不适用

Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsAcute Bacterial Skin and Skin Structure InfectionsMedDRA version: 17.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestations

EUCTR2014-000419-15-LVDurata Therapeutics International B.V.698

进行中（未招募）

不适用

EUCTR2014-000419-15-BGDurata Therapeutics International B.V.698

进行中（未招募）

不适用

Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsAcute Bacterial Skin and Skin Structure InfectionsMedDRA version: 17.0Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestations

EUCTR2014-000419-15-HUDurata Therapeutics International B.V.410

进行中（未招募）

不适用

EUCTR2014-000419-15-HRDurata Therapeutics International B.V.410

进行中（未招募）

1 期

An Efficacy and Safety Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS)

EUCTR2019-004256-11-ITMitsubishi Tanabe Development America Inc.380